Table 3.
RASwt | CMS1 | P* | CMS2 | P* | CMS3 | P* | CMS4 | P* | Chi-square P | CMS 1–4 | P* | CMS 1–4 left-sided | P* | CMS 1–4 right-sided | P* |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
(n = 315) | |||||||||||||||
FOLFIRI Cet | 61% | 0.54 | 88% | 0.043 | 74% | 0.13 | 76% | 0.049 | 67% | 0.049 | 71% | 0.06 | 52% | 0.81 | |
FOLFIRI Bev | 50% | 71% | 42% | 55% | 56% | 58% | 47% | ||||||||
Both arms | 55% | 78% | 61% | 66% | 0.027 | 61% | 65% | 49% | |||||||
(n = 123) | |||||||||||||||
FOLFIRI Cet | 40% | 0.58 | 58% | 0.46 | 50% | 0.70 | 40% | 0.054 | 39% | 0.28 | 40% | 0.38 | 40% | 0.75 | |
FOLFIRI Bev | 67% | 39% | 39% | 74% | 50% | 51% | 47% | ||||||||
Both arms | 57% | 47% | 44% | 56% | 0.71 | 45% | 46% | 44% | |||||||
(n = 438) | |||||||||||||||
FOLFIRI Cet | 54% | 0.59 | 81% | 0.03 | 66% | 0.11 | 63% | 0.73 | 59% | 0.29 | 63% | 0.26 | 47% | >0.99 | |
FOLFIRI Bev | 55% | 64% | 42% | 60% | 54% | 57% | 47% | ||||||||
Both arms | 55% | 71% | 55% | 62% | 0.051 | 57% | 60% | 47% |
CMS, consensus molecular subgroup; P*, two-sided Fisher’s exact test P; Cet, cetuximab; Bev, bevacizumab; RASwt, RAS wild-type.